ACT Annual Meeting, Nov 17-20, Austin, TX

Join CBSET and our partner Cilcare at the ACT 2024 Annual Meeting, November 17-20, at the J W Marriott in Austin, TX.

The 45th Annual Meeting will include a wide-ranging scientific program and educational courses, with distinguished plenary speakers, the popular Poster Session, an Awards Ceremony, and multiple professional networking events.

CBSET and Cilcare will be exhibiting in booth # 105.

Please contact us to meet up during the ACT Annual Meeting in Austin.




    Related CBSET & Cilcare Publications:

    Ototoxicity: a high risk to auditory function that needs to be monitored in drug development. Marie-Pierre Pasdelou, Lise Byelyayeva, Susanna Malmström, Sylvie Pucheu, Marie Peytavy, Hugo Laullier, Donald B. Hodges, Abraham R. Tzafriri, Gaëlle Naert. Frontiers in Molecular Neuroscience, 02 May 2024. Sec. Molecular Signalling and Pathways, Volume 17 - 2024 | https://doi.org/10.3389/fnmol.2024.1379743.

    Best Practices for the Conduct of Preclinical Ototoxicity Evaluation. John Keating, Director of Pathology, CBSET; Aurore Marie, Global Head, R&D Ops Management, Cilcare;  Christopher Toscano, Non-clinical Reviewer, FDA. Talking Tox Webinar, presented at the ACT 42nd Virtual Annual Meeting, Jan 20, 2022.

    HEAR THIS! Potential Therapeutics for COVID-19 Should Be Tested for Auditory Safety. Wahid Awad, PhD, Chief Business Officer, Cilcare; Michael Naimark, Director of Business Development, CBSET. World Pharma Today, August 24, 2020.

    Ototoxicity Related to Cisplatin: Does Gender Matter? Cyrille Sage, Aurore Marie, Randolph Abutin, Rami Tzafriri. Presented at the STP 38th Annual Symposium, June 23-27, 2019, in Raleigh, North Carolina. 

    Intracochlear Drug Delivery Systems: A Novel Approach Whose Time Has Come. Peppi M, Marie A, Belline C, Borenstein JT. Expert Opinion in Drug Delivery. 2018 Feb 26. doi: 10.1080/17425247.2018.1444026.

    wpt-cbset-cilcare-cover
    World Pharma Today: Auditory Therapy, Ototoxicity, and GLP Compliance: Will the promising market for ear disorder treatments follow ophthalmology’s dramatic growth curve?

    by Michael Naimark, Director of Business Development, CBSET, Inc. and Marie-Pierre Pasdelou, PharmD, founder and the Chief Development Officer, CILcare

    wpt-stem-cell-auditory-coverWorld Pharma Today: Stem Cell and Regenerative Therapies for Hearing Loss

    by Michael Naimark, Director of Business Development, CBSET, Inc. and Marie-Pierre Pasdelou, PharmD, founder and the Chief Development Officer, CILcare